News
- Author:
- Neil Osterweil
Publish date: December 6, 2015
Key clinical point: A first-in class small molecule drug improved hematologic parameters and reduced sickling of red blood cells.
News
- Author:
- Neil Osterweil
Publish date: December 6, 2015
Key clinical point: Bone marrow transplants from HLA-identical siblings are frequently curative of sickle-cell disease.
Major finding: Three-year...
Video
- Author:
- Neil Osterweil
Publish date: December 6, 2015
News
- Author:
- Neil Osterweil
Publish date: December 6, 2015
News
- Author:
- Neil Osterweil
Publish date: December 6, 2015
Key clinical point: Patients in first ALL remission may not be as adherent to 6MP maintenance therapy as they claim.
Major finding: In all, 40.4% ...
News
- Author:
- Neil Osterweil
Publish date: December 5, 2015
Red blood cells stored for up to 35 days were not inferior to more recently collected RBCs for tissue reoxygenation.
News
- Author:
- Neil Osterweil
Publish date: December 5, 2015
The first two patients treated had enhanced expression of B, T, and NK cells, with the cells continuing to show improvements.
News
- Author:
- Neil Osterweil
Publish date: December 5, 2015
Key clinical point: Gene therapy might safely and effectively correct an inherited immunodeficiency syndrome.
Major finding: Six of eight childre...
News
- Author:
- Neil Osterweil
Publish date: November 20, 2015
Key clinical point: Pneumonitis is an uncommon but potentially serious adverse event associated with PD-1/PD-L1 checkpoint inhibitor therapy.
Majo...
News
- Author:
- Neil Osterweil
Publish date: November 19, 2015
Key clinical point: Conjugating a metabolite of irinotecan to an antibody allows targeted delivery of the otherwise highly toxic drug.
Major findi...
News
- Author:
- Neil Osterweil
Publish date: November 18, 2015
Key clinical point: Inhibitors of CTLA-4 and PD-1/PD-L1 are associated with manageable immune-related adverse events.
Major finding: Cutaneous adv...
News
- Author:
- Neil Osterweil
Publish date: November 16, 2015
Key clinical point: AG-120 is a first-in-class inhibitor of IDH1 mutations that may drive oncogenesis.
Major finding: 10 of 20 patients with glio...
News
- Author:
- Neil Osterweil
Publish date: November 14, 2015
A novel pan-AKT inhibitor shrinks tumors in patients harboring a mutation in AKT1.
News
- Author:
- Neil Osterweil
Publish date: November 10, 2015
Key clinical point:Inhibition of TRK gene fusion products is a novel strategy for treating cancer.
Major finding: Three of three patients evaluabl...
News
- Author:
- Neil Osterweil
Publish date: November 9, 2015
Key clinical point: A tyrosine kinase inhibitor targeted to mutant EGFR showed good activity against leptomeningeal metastases in patients with NS...
